Results 201 to 210 of about 22,545,234 (252)
Some of the next articles are maybe not open access.
B-cell function in patients with chronic lymphocytic leukemia
Klinische Wochenschrift, 1982Using a reverse hemolytic protein A plaque assay, spontaneous and pokeweed mitogen (PWM)-induced immunoglobulin (Ig) secretion was determined in peripheral blood from 22 patients with B1-chronic lymphocytic leukemia (CLL), one patient with B2-CLL, and one patient with suppressor T-CLL. Diagnoses were established by cytological and histological criteria
G, Sieber +3 more
openaire +2 more sources
Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia
New England Journal of Medicine, 2008A diagnosis of chronic lymphocytic leukemia (CLL) requires a count of over 5000 circulating CLL-phenotype cells per cubic millimeter. Asymptomatic persons with fewer CLL-phenotype cells have monoclonal B-cell lymphocytosis (MBL). The goal of this study was to investigate the relation between MBL and CLL.We investigated 1520 subjects who were 62 to 80 ...
Andy C, Rawstron +10 more
openaire +2 more sources
Multidrug Resistance in B-Cell Chronic Lymphocytic Leukemia
Acta Haematologica, 2009Multidrug resistance (MDR) was investigated in peripheral blood cells isolated from 40 patients with B cell chronic lymphocytic leukemia (B-CLL) and from 7 healthy volunteers, using a flow cytometric assay that detects cellular efflux of the fluorescent dye rhodamine 123 (Rh 123), which has been demonstrated to be transported from the cell by the P ...
I, Grulois +5 more
openaire +2 more sources
The normal counterpart to the chronic lymphocytic leukemia B cell
Best Practice & Research Clinical Haematology, 2007Chronic lymphocytic leukemia (CLL) is characterized by the monoclonal expansion of small mature-looking B cells that accumulate in the blood, marrow, and lymphoid organs, and have a remarkable phenotypic homogeneity. By definition, CLL cells co-express CD5 and CD23 with faint to undetectable amounts of monoclonal surface immunoglobulins (sIg).
Caligaris Cappio F +1 more
openaire +2 more sources
Alemtuzumab for B-cell chronic lymphocytic leukemia
Expert Review of Anticancer Therapy, 2008Alemtuzumab (Campath, MabCampath) is a humanized therapeutic monoclonal antibody (mAb) that recognizes the CD52 antigen expressed on normal and neoplastic lymphoid cells. This mAb is active in previously treated patients with B-cell chronic lymphocytic leukemia (B-CLL) refractory to alkylating agents and purine nucleoside analogs.
openaire +2 more sources
Angiogenesis is increased in B-cell chronic lymphocytic leukemia
Blood, 2001Aguayo and colleagues recently reported elevated levels of vascular endothelial growth factor (VEGF) in the cells of B-cell chronic lymphocytic leukemia (CLL).[1][1] When discussing the possible significance of the elevated VEGF levels in CLL, the authors cite their prior abstract in which ...
LoAnn Peterson, Ameet R. Kini, Neil Kay
openaire +2 more sources
Genetic Features of B‐Cell Chronic Lymphocytic Leukemia
Reviews in Clinical and Experimental Hematology, 2000The genetic features of B‐cell chronic lymphocytic leukemia CLL) are currently being reassessed by molecular cytogenetic techniques such as fluorescence in situ hybridization FISH). Conventional cytogenetic studies by chromosome banding are difficult in CLL mainly because of the low in vitro mitotic activity of the tumor cells, which leads to poor ...
S, Stilgenbauer, P, Lichter, H, Döhner
openaire +2 more sources
Stereotyped B-cell receptors in chronic lymphocytic leukemia
Leukemia & Lymphoma, 2014Over the last decade, immunogenetic analysis of B-cell receptor immunoglobulins (BcR IGs) has proved to be a particularly fruitful field in chronic lymphocytic leukemia (CLL), not only for understanding disease pathogenesis but also for discriminating clinical subgroups with markedly distinct course and outcome.
Andreas, Agathangelidis +3 more
openaire +2 more sources
Targeting B Cell Signaling in Chronic Lymphocytic Leukemia
Current Oncology Reports, 2017In recent years, a revolution in the management of chronic lymphocytic leukemia (CLL) has centered on the targeting of the B cell receptor (BCR) signaling pathway. Our improved understanding of the biology of cell signaling in CLL and the development of oral kinase inhibitors directed at the BCR pathway has led to the approval of two new agents and has
Jon E, Arnason, Jennifer R, Brown
openaire +2 more sources
B-cell receptor signaling in chronic lymphocytic leukemia
Blood, 2011Abstract The B-cell receptor (BCR) is a key survival molecule for normal B cells and for most B-cell malignancies. Recombinatorial and mutational patterns in the clonal immunoglobulin (Ig) of chronic lymphocytic leukemia (CLL) have revealed 2 major IgMD-expressing subsets and an isotype-switched variant, each developing from distinct ...
Stevenson, FK +4 more
openaire +3 more sources

